
|Videos|October 20, 2016
High Cost Drug Launches and Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses lessons the specialty industry learned from the impact of high cost drug launches for hepatitis C and high cholesterol.
Advertisement
Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses lessons the specialty industry learned from the impact of high cost drug launches for hepatitis C and high cholesterol.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Obinutuzumab-Bendamustine Produces High Response Rates in Chinese Patients With Indolent B-Cell Lymphomas
2
State Pharmacy Boards Must Step Up Against Illegal Retatrutide
3
New CKD Outcome Set Tells Pharmacists What to Measure
4
GLP-1s and the HCM–Sleep Apnea–Obesity Connection
5





































































































